Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes
Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes
This study evaluates the change of insulin resistance and glucose metabolism of patients with
 panniculitis associated acquired lipodystrophy syndrome and type 1 diabetes with the
 treatment of cyclophosphamide.
Patients with panniculitis associated acquired lipodystrophy syndrome and type 1 diabetes
 have difficulty in blood glucose management due to the presence of both severe insulin
 resistance and complete insulin deficiency. It is often necessary to use insulin doses
 several times that of other children of the same age with type 1 diabetes.

 Since autoimmune response is the main cause of panniculitis associated acquired lipodystrophy
 syndrome, immunosuppressive agents can suppress immune response, prevent and alleviate the
 progression of panniculitis and acquired lipodystrophy syndrome, and improve insulin
 resistance caused by subcutaneous fat deficiency.

 Cyclophosphamide is a classic immunosuppressive agent. This study hopes to improve insulin
 resistance of patients with panniculitis associated acquired lipodystrophy syndrome and type
 1 diabetes by cyclophosphamide treatment, thereby reducing insulin dosage and improving
 glucose metabolism.
Inclusion Criteria:

 1. Meet the diagnostic criteria of type 1 diabetes mellitus: clinical manifestations of
 typical diabetes mellitus include polyphagia, polyuria, weight loss, or diabetic
 ketoacidosis, confirmed by blood sugar level, islet function and autoimmune antibody.

 2. Meet the diagnostic criteria for panniculitis: fat biopsy suggests inflammatory
 infiltration.

 3. Meet the diagnostic criteria for acquired lipodystrophy syndrome: childhood onset,
 clinically no nutritional deficiency or catabolism, systemic or partial subcutaneous
 fat reduction, genetic testing to exclude congenital lipodystrophy syndrome; low
 leptin level and autoantibodies can aid in diagnosis.

 Exclusion Criteria:

 1. Mature and effective treatment methods are available.

 2. HIV, HBV and HCV were positive.

 3. A the active period of infection.

 4. At the active stage of malignant tumors.

 5. Combination of other fatal diseases.

 6. Existence of mental and psychological diseases.